<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687060</url>
  </required_header>
  <id_info>
    <org_study_id>1U01HL142104-01</org_study_id>
    <nct_id>NCT03687060</nct_id>
  </id_info>
  <brief_title>INcreasing Statin Prescribing in HIV Behavioral Economics REsearch</brief_title>
  <acronym>INSPIRE</acronym>
  <official_title>Behavioral Economics and Implementation Research to Reduce Cardiovascular Risk in HIV-Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RAND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Olive View-UCLA Education &amp; Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease is a major cause of morbidity and mortality among people living with
      HIV. Recent studies have demonstrated that patients with HIV experience a 50-100% increased
      risk of myocardial infarction and stroke compared to HIV-uninfected persons. They also face
      higher risks of stroke, sudden death, and heart failure. However, evidence-based statin
      therapy—which is safe in this population and highly effective at reducing cardiovascular
      risk—is under-prescribed. The investigators propose a multi-level intervention to increase
      evidence-based statin prescribing by addressing barriers at these levels. The implementation
      intervention includes two strategies: (1) tailored education at the leadership, provider, and
      patient levels, and (2) behavioral economics-informed feedback for providers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Stepped-wedge cluster randomized trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proportion of PLWH with cardiovascular risk factors seen by a physician receiving statin therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Organization Level</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Provider Level</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Level</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Knowledge assessment</intervention_name>
    <description>Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.</description>
    <arm_group_label>Organization Level</arm_group_label>
    <arm_group_label>Patient Level</arm_group_label>
    <arm_group_label>Provider Level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Education Intervention</intervention_name>
    <description>Education intervention will be adapted from the the findings of these interviews and focus groups.
Clinics will be randomized to receive the &quot;education intervention and feedback&quot; implementation strategies at different times.
Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.
Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV.</description>
    <arm_group_label>Provider Level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Provider Feedback</intervention_name>
    <description>Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.</description>
    <arm_group_label>Provider Level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 40 years

          -  have been diagnosed with HIV

          -  LDL ≥ 190, diabetes and LDL ≥ 70

          -  or 10-year ASCVD risk ≥ 7.5%

          -  or history of heart attack, stroke, or peripheral vascular disease

          -  care for patients with HIV at least 1/2 day each week (physicians)

          -  work at participating clinics (physicians)

        Exclusion Criteria:

          -  unable to provide written, informed consent

          -  not at participating clinic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Ladapo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Cunningham, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JWCH Institute</name>
      <address>
        <city>Commerce</city>
        <state>California</state>
        <zip>90040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antelope Valley Health Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watts Health Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oasis Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>To Help Everyone Health and Wellness Centers</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venice Family Clinic</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View-UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarzana Treatment Centers, Inc.</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So-Armah K, Freiberg MS, Lloyd-Jones DM. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am J Cardiol. 2016 Jan 15;117(2):214-20. doi: 10.1016/j.amjcard.2015.10.030. Epub 2015 Nov 6.</citation>
    <PMID>26639041</PMID>
  </reference>
  <reference>
    <citation>Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017 Jul;4(7):e284-e294. doi: 10.1016/S2352-3018(17)30075-9. Epub 2017 Apr 13. Erratum in: Lancet HIV. 2017 Jul;4(7):e283.</citation>
    <PMID>28416195</PMID>
  </reference>
  <reference>
    <citation>Masiá M, Bernal E, Robledano C, Padilla S, López N, Martínez E, Gutiérrez F. Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk. J Antimicrob Chemother. 2014 Nov;69(11):3051-6. doi: 10.1093/jac/dku269. Epub 2014 Jul 18.</citation>
    <PMID>25038306</PMID>
  </reference>
  <reference>
    <citation>Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728.</citation>
    <PMID>23459863</PMID>
  </reference>
  <reference>
    <citation>Stein JH. Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin? Top Antivir Med. 2016 Dec-2017 Jan;23(5):169-73. Review.</citation>
    <PMID>27398770</PMID>
  </reference>
  <reference>
    <citation>Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis. 2016 Dec 1;63(11):1508-1516. Epub 2016 Sep 9.</citation>
    <PMID>27613562</PMID>
  </reference>
  <reference>
    <citation>Ladapo JA, Richards AK, DeWitt CM, Harawa NT, Shoptaw S, Cunningham WE, Mafi JN. Disparities in the Quality of Cardiovascular Care Between HIV-Infected Versus HIV-Uninfected Adults in the United States: A Cross-Sectional Study. J Am Heart Assoc. 2017 Nov 14;6(11). pii: e007107. doi: 10.1161/JAHA.117.007107.</citation>
    <PMID>29138182</PMID>
  </reference>
  <reference>
    <citation>Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008 Feb;4(1):269-86.</citation>
    <PMID>18728716</PMID>
  </reference>
  <reference>
    <citation>Lublóy Á. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014 Oct 20;14:469. doi: 10.1186/1472-6963-14-469. Review.</citation>
    <PMID>25331607</PMID>
  </reference>
  <reference>
    <citation>Doroodchi H, Abdolrasulnia M, Foster JA, Foster E, Turakhia MP, Skelding KA, Sagar K, Casebeer LL. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008 Jul 8;9:42. doi: 10.1186/1471-2296-9-42.</citation>
    <PMID>18611255</PMID>
  </reference>
  <reference>
    <citation>Trinkley KE, Malone DC, Nelson JA, Saseen JJ. Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study. Ther Adv Chronic Dis. 2016 Sep;7(5):220-8. doi: 10.1177/2040622316657328. Epub 2016 Aug 11.</citation>
    <PMID>27583122</PMID>
  </reference>
  <reference>
    <citation>Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012 May-Jun;6(3):208-15. doi: 10.1016/j.jacl.2012.03.003.</citation>
    <PMID>22658145</PMID>
  </reference>
  <reference>
    <citation>Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010 Spring;14(1):4-10.</citation>
    <PMID>20740125</PMID>
  </reference>
  <reference>
    <citation>Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013 Sep-Oct;7(5):472-83. doi: 10.1016/j.jacl.2013.03.001. Epub 2013 Mar 13.</citation>
    <PMID>24079289</PMID>
  </reference>
  <reference>
    <citation>Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.</citation>
    <PMID>19664226</PMID>
  </reference>
  <reference>
    <citation>Aarons GA. Mental health provider attitudes toward adoption of evidence-based practice: the Evidence-Based Practice Attitude Scale (EBPAS). Ment Health Serv Res. 2004 Jun;6(2):61-74.</citation>
    <PMID>15224451</PMID>
  </reference>
  <reference>
    <citation>Lehman WE, Greener JM, Simpson DD. Assessing organizational readiness for change. J Subst Abuse Treat. 2002 Jun;22(4):197-209.</citation>
    <PMID>12072164</PMID>
  </reference>
  <reference>
    <citation>Glisson C, Landsverk J, Schoenwald S, Kelleher K, Hoagwood KE, Mayberg S, Green P; Research Network on Youth Mental Health. Assessing the organizational social context (OSC) of mental health services: implications for research and practice. Adm Policy Ment Health. 2008 Mar;35(1-2):98-113. Epub 2007 Dec 18.</citation>
    <PMID>18085434</PMID>
  </reference>
  <reference>
    <citation>Weiner BJ, Amick H, Lee SY. Conceptualization and measurement of organizational readiness for change: a review of the literature in health services research and other fields. Med Care Res Rev. 2008 Aug;65(4):379-436. doi: 10.1177/1077558708317802. Epub 2008 May 29. Review.</citation>
    <PMID>18511812</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Joseph Ladapo, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

